Your browser doesn't support javascript.
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.
Lempp, Florian A; Soriaga, Leah B; Montiel-Ruiz, Martin; Benigni, Fabio; Noack, Julia; Park, Young-Jun; Bianchi, Siro; Walls, Alexandra C; Bowen, John E; Zhou, Jiayi; Kaiser, Hannah; Joshi, Anshu; Agostini, Maria; Meury, Marcel; Dellota, Exequiel; Jaconi, Stefano; Cameroni, Elisabetta; Martinez-Picado, Javier; Vergara-Alert, Júlia; Izquierdo-Useros, Nuria; Virgin, Herbert W; Lanzavecchia, Antonio; Veesler, David; Purcell, Lisa A; Telenti, Amalio; Corti, Davide.
  • Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
  • Soriaga LB; Vir Biotechnology, San Francisco, CA, USA.
  • Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
  • Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Noack J; Vir Biotechnology, San Francisco, CA, USA.
  • Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Zhou J; Vir Biotechnology, San Francisco, CA, USA.
  • Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
  • Joshi A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Agostini M; Vir Biotechnology, San Francisco, CA, USA.
  • Meury M; Vir Biotechnology, San Francisco, CA, USA.
  • Dellota E; Vir Biotechnology, San Francisco, CA, USA.
  • Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Martinez-Picado J; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Vergara-Alert J; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain.
  • Izquierdo-Useros N; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
  • Virgin HW; IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, Bellaterra (Cerdanyola del Vallès), Spain.
  • Lanzavecchia A; IrsiCaixa AIDS Research Institute, Badalona, Spain.
  • Veesler D; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.
  • Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
  • Telenti A; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.
  • Corti D; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Nature ; 598(7880): 342-347, 2021 10.
Article in English | MEDLINE | ID: covidwho-1379317
ABSTRACT
SARS-CoV-2 infection-which involves both cell attachment and membrane fusion-relies on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically found at low levels in the respiratory tract1-3, suggesting that there may be additional mechanisms facilitating infection. Here we show that C-type lectin receptors, DC-SIGN, L-SIGN and the sialic acid-binding immunoglobulin-like lectin 1 (SIGLEC1) function as attachment receptors by enhancing ACE2-mediated infection and modulating the neutralizing activity of different classes of spike-specific antibodies. Antibodies to the amino-terminal domain or to the conserved site at the base of the receptor-binding domain, while poorly neutralizing infection of ACE2-overexpressing cells, effectively block lectin-facilitated infection. Conversely, antibodies to the receptor binding motif, while potently neutralizing infection of ACE2-overexpressing cells, poorly neutralize infection of cells expressing DC-SIGN or L-SIGN and trigger fusogenic rearrangement of the spike, promoting cell-to-cell fusion. Collectively, these findings identify a lectin-dependent pathway that enhances ACE2-dependent infection by SARS-CoV-2 and reveal distinct mechanisms of neutralization by different classes of spike-specific antibodies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / Lectins Limits: Animals / Female / Humans Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03925-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / Lectins Limits: Animals / Female / Humans Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03925-1